NASDAQ · PRFX
Healthcare · Drug Manufacturers - Specialty & Generic
$0.88
Up+$0.01 (+1.42%)
Updated Oct 7, 2026, 4:48 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PRFX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
PRFX closed at $0.88 after 21 trading sessions, down 6.86% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.8954 | $0.925 | $0.8801 | $0.8802 | 35.76K |
| Oct 5, 2026 | $0.9195 | $0.9289 | $0.872 | $0.8843 | 68.9K |
| Oct 2, 2026 | $0.9203 | $0.9389 | $0.9103 | $0.92 | 51.89K |
| Oct 1, 2026 | $0.9656 | $0.9656 | $0.9503 | $0.9503 | 22.96K |
| Sep 30, 2026 | $0.967 | $0.9775 | $0.9502 | $0.9503 | 10.27K |
| Sep 29, 2026 | $0.9649 | $0.9699 | $0.945 | $0.945 | 11.83K |
| Sep 28, 2026 | $0.99 | $1.02 | $0.96 | $0.9717 | 41.47K |
| Sep 25, 2026 | $0.989 | $1.0193 | $0.9501 | $0.9767 | 43.48K |
| Sep 24, 2026 | $1.00 | $1.01 | $0.9705 | $0.9821 | 106.44K |
| Sep 23, 2026 | $0.9551 | $1.09 | $0.9551 | $1.00 | 164.33K |
| Sep 22, 2026 | $0.9767 | $0.9929 | $0.901 | $0.9305 | 61.94K |
| Sep 21, 2026 | $1.02 | $1.08 | $0.9502 | $0.9616 | 127.35K |
| Sep 18, 2026 | $1.05 | $1.06 | $1.005 | $1.02 | 96K |
| Sep 17, 2026 | $1.00 | $1.14 | $0.9713 | $1.02 | 276.13K |
| Sep 16, 2026 | $0.911 | $1.27 | $0.9108 | $1.01 | 6.09M |
| Sep 15, 2026 | $0.8598 | $0.9189 | $0.8548 | $0.90 | 79.48K |
| Sep 14, 2026 | $0.909 | $0.909 | $0.8551 | $0.8605 | 23.81K |
| Sep 11, 2026 | $0.9121 | $0.9295 | $0.8519 | $0.8601 | 88.81K |
| Sep 10, 2026 | $0.9613 | $0.9613 | $0.9207 | $0.9275 | 51.38K |
| Sep 9, 2026 | $0.9831 | $0.9831 | $0.935 | $0.9503 | 36.71K |
| Sep 8, 2026 | $0.99 | $0.99 | $0.93 | $0.945 | 26.62K |
The latest Smart Investors Daily articles mentioning PRFX.
Company
Market Activity
Research & News
PRFX research
Company profile and research snapshot.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 24, 2024 | Maxim Group | Hold | — |
| Jun 26, 2024 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 27, 2026
First-Half 2026 and Recent Highlights:Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheetLayerBio advancing the operational and clinical preparations required
Benzinga · Mar 27, 2026
LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strategyDeepSolar advances from acquisition to early commercial deployment
Benzinga · Mar 17, 2026
PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") today announced a commercial collaboration agreement with Blade Ranger Ltd. (TASE: BLRN) designed to accelerate the commercial expansion of its DeepSolar
Benzinga · Feb 11, 2026
PRF Technologies (Nasdaq: PRFX) ("PRF" or the "Company"), through its DeepSolar™ AI-driven solar analytics business unit, today announced the signing of a software-as-a-service (SaaS) agreement with Shikun &
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRFX.
No results
No recent SID articles mention PRFX.
